Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Closely tracking Jensen Huang's visit to Korea! A website monitoring his itinerary goes viral as traffic surges rapidly.

Closely tracking Jensen Huang's visit to Korea! A website monitoring his itinerary goes viral as traffic surges rapidly.

格隆汇格隆汇2026/06/04 12:48
Show original
格隆汇 June 4|According to market news, as NVIDIA CEO Jensen Huang is set to begin his visit to South Korea, a website tracking his whereabouts has attracted widespread attention. Starting from this Tuesday, the site named "Jensen Huang's Footsteps" has gained significant focus, with its visitor numbers surging sharply over the past few days. As of June 4, the cumulative number of visitors to the website has exceeded 50 thousand. The site provides real-time tracking of Jensen Huang's itinerary in South Korea and simultaneously broadcasts the stock price trends of related listed Korean companies. As of 9 am (UTC+8) on June 4, there were about 300 online visitors, and cumulative visits surpassed 54 thousand. The website was built by an independent developer, who automatically aggregates reports from major media outlets about Jensen Huang, displaying his meeting schedule and estimated locations on an interactive map.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage